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Abstract
Background: Acute tubulointerstitial nephritis (ATIN) is an important cause of acute kidney injury and often a
potentially reversible disease. However, the role of steroids in ATIN remains controversial and the underlying
mechanisms remain unresolved.
Methods: A total of 113 adult patients with biopsy-proven ATIN were recruited from three tertiary referral centers.
Of 102 patients with idiopathic or drug-induced ATIN, outcomes such as renal recovery, end-stage renal disease,
and all-cause mortality were compared between the steroid-treated and non-treated groups. Plasma and urine
inflammatory cytokine levels at the time of biopsy were analyzed in patients (n = 33) using a bead-based multiplex
assay and compared with those of healthy individuals (n = 40).
Results: Steroids were used in 92 (81.4%) of the total patients and in 82 (80.3%) patients with idiopathic or drug-
induced ATIN. The rate of renal recovery and the risks of end-stage renal disease and mortality were not different
between the steroid-treated and non-treated groups. Despite using a propensity score matching method (n = 20 in
each group), none of the outcomes were different between the two groups. Several cytokines, such as monocyte
chemotactic protein-1, interferon-α, and interleukin-6 and interleukin-8 levels, were markedly elevated in plasma
and urine of patients compared with those in healthy individuals. However, cytokines related to Th2 response, such
as IL-10, IL-33, were not different between the two groups.
Conclusions: Steroid use does not affect the overall outcome of ATIN. Based on the fact that targeting therapy
should be investigated to improve outcomes, the present cytokine results will be helpful for developing a novel
therapy for ATIN.
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Background
Acute tubulointerstitial nephritis (ATIN) is an important
cause of acute kidney injury, and it causes inflammation
and dysfunction mainly in the tubules, without affecting
glomeruli and vasculature. ATIN accounts for 0.5–2.6%
of all kidney biopsies and 5–27% of unexplained acute
kidney injury [1–4]. The etiology of ATIN includes
drug-induced, autoimmune disease, infection, malig-
nancy, and others [5]. ATIN was originally thought to be
mainly caused by infection, but a drug-induced cause
has become the main etiology in recent years [4, 6–8].
With regard to the pathogenesis of ATIN, a hypersen-
sitivity reaction to kidney antigens is thought to play a
major role. ATIN occurs only in a small percentage of
individuals and in a dose-independent manner, and
sometimes exhibits extra-renal manifestations related to
hypersensitivity [9, 10]. However, the underlying mech-
anism of ATIN is not fully understood. In previous
retrospective reviews, steroids were mostly used or rec-
ommended to be used for ATIN [11–17]. Additionally,
oral prednisolone at 1 mg/kg/day for ATIN was usually
used with or without pulse therapy of methylpredniso-
lone over the next 3–12 weeks [4]. However, there is no
clear consensus on the effectiveness of steroids because
there have been no prospective, randomized, controlled
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trials of steroid use in relation to the clinical course of
ATIN to date.
Cohort studies on patients with ATIN and possible ef-
fects of steroids have been conducted [11–16]. However,
further studies on patients with ATIN and various char-
acteristics are required to determine the significance of
steroid capacity. Research on the underlying mechanism
may also provide information on this issue. The present
cohort study aimed to examine the effect of steroids on
renal outcomes, including recovery of ATIN, and the
risks of end-stage renal disease (ESRD) and mortality.
Subsequent analyses of cytokine and chemokine, which
are possibly related to tubular inflammation, were con-
ducted to provide a clue of the pathophysiology of
ATIN.
Methods
Patients and data collection
The study design was approved by the institutional re-
view boards of all involved centers (nos.
H-1801-043-914, B-1801/447–409, and 20,180,124/30–
2018-3/023) and complied with the Declaration of
Helsinki. Informed consents were waived under this ap-
proval. A total of 7196 patients had a kidney biopsy per-
formed at three tertiary referral hospitals (Seoul
National University Hospital, Boramae Medical Center,
and Seoul National University Bundang Hospital) over
18 years (from January 2000 to December 2017). Among
them, 270 patients were diagnosed with ATIN. Patients
were excluded from the analysis if they also had glomer-
ulonephritis (n = 122), pyelonephritis (n = 3), or other
pathologies, including thrombotic microangiopathy (n =
6) and atheroembolism (n = 1), they were younger than
18 years (n = 5), and they had an insufficient follow-up
period (< 3months) (n = 11). We also excluded patients
without azotemia at the time of biopsy (n = 9: 5 were
renal tubular acidosis, 2 were drug-induced ATIN, 1 was
renal tuberculosis, and 1 was related with Sjögren syn-
drome) because the effect of steroids on outcomes of
ATIN could not be examined in these patients. Finally,
the analyzed cohort comprised 113 patients.
All of the patients’ clinical data such as age, sex, body
mass index, comorbidities, including diabetes mellitus,
hypertension, and chronic kidney disease, renal out-
comes, and steroid treatment for ATIN, were collected.
Baseline blood laboratory data, such as serum creatinine,
hemoglobin, cholesterol, uric acid, and albumin levels,
were measured. The dipstick test was used to evaluate
proteinuria, which was semi-quantitatively scored.
Microscopic evaluation of urine was performed to define
hematuria and pyuria. The random urine protein to cre-
atinine ratio was measured at the time of biopsy, but this
variable was not available in five patients. The etiology
of ATIN was classified into idiopathic if there were no
specific factors inducing kidney dysfunction. Two
nephropathologists reviewed all of the slides and
semi-quantitative graded scores for tubular atrophy and
interstitial fibrosis, and leukocyte infiltration, according
to the Banff working classification [18].
Renal recovery, which was primary outcome, was de-
fined as a decrease in serum creatinine levels to ≤1 .3mg/
dL or ≥ 50% from its peak value. Renal recovery was evalu-
ated at multiple time points, such as at 6months after kid-
ney biopsy and at the last follow-up. The outcome of
ESRD was defined as initiation of renal replacement ther-
apy or kidney transplantation due to failed kidney func-
tion. The events of ESRD and all-cause mortality were
obtained from the Kidney Renal Registry and the National
Database of Statistics Korea, respectively.
Cytokine analysis
Thirty three patients’ plasma and urine were acquired at
the time of kidney biopsy and before any treatment was
provided. Forty healthy individuals’ plasma and urine
were also recruited at the time of a health checkup for
comparison with the patients. We performed a
bead-based multiplex assay according to the manufac-
turer’s instruction (LEGENDplex™; BioLegend, San
Diego, CA, USA). This assay included 13 cytokines and
chemokines which were known to play a crucial role in
renal ischemia-reperfusion injury [19–22] and were pos-
sibly related to tubular inflammation pathways [23], such
as interleukin (IL)-1β, interferon (IFN)-α2, IFN-γ, tumor
necrosis factor-α, monocyte chemo-attractant protein-1,
IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and
IL-33. Cytokine- and chemokine-bound beads were read
on a flow cytometer (BD LSRFortessa™; BD Biosciences,
San Jose, CA, USA). Data were analyzed using the ana-
lysis program recommended by the manufacturer’s in-
structions (LEGENDplex™, Data Analysis v8.0;
VigeneTech, Carlisle, MA, USA).
Statistical analysis
All statistical analyses were performed using SPSS version
23.0 (IBM Corp., Armonk, NY, USA) and R software (ver-
sion 3.4.1; The Comprehensive R Archive Network: http://
cran.r-project.org). Continuous variables are expressed as
the mean value and standard deviation if they had a normal
distribution and as the median value and interquartile range
if they were not normally distributed. A normality test was
performed using the Kolomogrov–Sirnov test. Categorical
variables are expressed as proportions. The chi-square test
was used for comparison of categorical variables (Fisher’s
exact test if not applicable) and the Student’s t-test was used
for continuous variables. The Mann–Whitney test was used
if variables were not normally distributed. Analysis of vari-
ance analysis was used when normality was satisfied for
comparison between group, and the Kruskal–Wallis test
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was used if normality was not satisfied. Logistic and Cox
proportional hazard ratio models were conducted to calcu-
late odds ratios (ORs) and hazard ratios (HRs) of the out-
come risk, respectively. All of the covariates shown in
Table 1, except for the random urine protein to creatinine
ratio (missing in five cases), were adjusted in the multi-
variate models. To assess the effect of steroids in ATIN,
we pooled the data of three previous retrospective cohort
studies, and compared the ESRD progression rate between
the steroid-treated and non-treated groups. Pooled
estimates of the relative risks and 95% confidence intervals
(95% CIs) were obtained using the DerSimonian and Laird
random effects model. Heterogeneity was assessed using
the Cochran Q statistic and I2. All P values were set to
two-sided, and values ≤0.05 were defined as significant.
Results
Baseline characteristics
Baseline characteristics of the patients are shown in
Table 1. The etiology of ATIN was idiopathic in 77
Table 1 Baseline characteristics of study subjects according to the etiology
Variable All patients (n = 113) Idiopathic (n = 77) Drug induced (n = 25) Autoimmune (n = 5) Othersa (n = 6) P-valueb
Age (year) 58.3 ± 15.2 57.2 ± 15.4 62.7 ± 12.8 58.0 ± 22.6 54.7 ± 15.4 0.428
Female (%) 40.7 45.5 28.0 20.0 50.0 0.338
Body mass index (kg/m2) 23.3 ± 3.6 23.5 ± 3.4 23.2 ± 4.1 22.9 ± 4.0 20.5 ± 2.5 0.263
Comorbidities (%)
Diabetes mellitus 30.1 35.1 20.0 0 33.3 0.255
Hypertension 40.7 41.6 44.0 40.0 16.7 0.687
Chronic kidney disease 11.5 9.1 20.0 0 16.7 0.330
Blood findings
Peak sCr (mg/dL) 4.50 (3.02–7.23) 4.35 (3.02–6.40) 5.42 (3.70–9.70) 2.61 (2.50–7.02) 5.36 (3.94–7.85) 0.362
sCr at biopsy (mg/dL) 3.77 (2.51–5.90) 3.50 (2.67–5.58) 3.91 (3.02–8.80) 2.50 (2.04–5.93) 4.54 (2.48–7.68) 0.528
Hemoglobin (g/dL) 10.1 ± 1.7 10.0 ± 1.6 10.4 ± 1.8 10.2 ± 1.9 10.1 ± 1.6 0.785
Cholesterol (mg/dL) 139.0 (119.0–165.0) 139.0 (121.0–167.0) 143.0 (116.0–166.0) 127.0 (111.0–146.0) 127.0 (101.0–149.0) 0.338
Uric acid (mg/dL) 6.1 (4.6–8) 5.9 (4.2–8) 6.3 (5.1–8) 5.3 (3.8–7.4) 7.6 (5.1–8.7) 0.665
Albumin (g/dL) 3.5 (3–3.9) 3.5 (3.1–3.9) 3.3 (2.9–3.9) 2.4 (2.3–3.7) 3.7 (3.5–3.9) 0.279
Proteinuria (%) 0.886
- or trace 27.4 31.2 20.0 20.0 16.7
1+ 36.3 32.5 36.0 60.0 66.7
2+ 24.8 24.7 28.0 20.0 16.7
≥ 3+ 11.5 11.7 16.0 0 0
Hematuria (%) 40.7 35.1 60.0 40.0 33.3 0.175
Pyuria (%) 58.4 57.1 60.0 60.0 66.7 1.000
uPCR (g/g) 1.3 (0.7–2.5) 1.3 (0.8–2.5) 1.3 (0.7–4.7) 1.1 (1.0–1.5) 1.7 (1.2–1.9) 0.865
Dialysis at biopsy (%) 30.1 24.7 44.0 40.0 33.3 0.251
Steroid use (%) 81.4 79.2 84.0 100 83.3 0.892
TA/IF (%) 0.378
None 15.9 10.4 24.0 20.0 50.0
Milde 33.6 33.8 36.0 40.0 16.7
Moderate 39.8 44.2 28.0 40.0 33.3
Severe 10.6 11.7 12.0 0 0
Leukocyte infiltration (%) 0.906
Mild 17.7 15.6 24.0 20.0 16.7
Moderate 38.1 41.6 28.0 40.0 33.3
Severe 44.2 42.9 48.0 40.0 50.0
Follow-up duration (months) 33 (19–55) 37 (19–54) 24 (19–60) 48 (30–56) 16 (8–24) 0.316
Data are n (%) or mean (±standard deviation) or median (interquartile range)
sCr serum creatinine, uPCR random urine protein to creatinine ratio, TA/IF tubular atrophy and interstitial fibrosis
aOthers included 5 cases of malignancy; and 1 case of infection
bP-value was obtained from Kruskal-Wallis test or ANOVA test between groups
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(68.1%) patients, drug-induced in 25 (22.1%), auto-
immune in five (4.4%), malignancy in five (4.4%), and in-
fection in one (0.8%). In the case of drug-induced
etiology, herbal medication was the most common cause
(n = 8, 32%), followed by nonsteroidal anti-inflammatory
drugs or salicylate (n = 6, 24%), antibiotics (n = 6, 24%),
proton pump inhibitors (n = 2, 8%), and others (2 cases
of oxaliplatin, 1 case of tranexamic acid). In the case of
autoimmune ATIN, there were three cases of
anti-neutrophil cytoplasmic antibody-associated vascu-
litis, one case of tubulointerstitial nephritis and uveitis,
and one case of Sjögren syndrome. All cases of malig-
nancy (n = 5) were multiple myeloma, and
infectious-ATIN was associated with Hantaan virus.
The mean age of the patients was 58 (±15) years and
60% of them were men. At the time of biopsy, the median
value of serum creatinine was 3.77mg/dL and the peak
level was 4.50mg/dL. Dialysis at the time of biopsy was
performed in 30.1% of patients, and steroids were used for
81.4% of patients. Patients with autoimmune disease or
malignancy were treated with steroids, but the patient
with infectious ATIN was not treated. The patients were
followed up for a median of 33months (interquartile
range, 19–55months; maximum of 12 years).
Overall renal outcomes
Table 2 shows the overall renal outcomes according to
the etiology of ATIN. The rate of renal recovery was
54.9% at 6 months after biopsy and 73.5% during the en-
tire follow-up period. The rate of ESRD progression was
25.7% and the all-cause mortality rate was 17.7% in all
patients. Of five patients with malignancy-associated
ATIN who were included in the others category, four
progressed to ESRD and died. This was the reason for
differences in the rates of renal recovery and mortality
among the groups.
Effect of steroids on renal outcome
Steroid use in cases of autoimmune diseases and mul-
tiple myeloma was essential for treating the diseases,
and steroid use in infectious disease was usually not rec-
ommended. Therefore, patients with autoimmune- and
malignancy-associated, and infectious ATIN were ex-
cluded from the analyses to determine the effect of
steroid use. To evaluate the effect of steroid use on out-
comes, 102 patients with idiopathic and drug-induced
ATIN were analyzed after stratification by the use of
steroids. Steroids were used in 80.3% of patients, and
the median value of initial steroid dose was 30mg/day
(30–60 mg/day as an equivalent dosage for prednisol-
one) and the median duration of use was 14 weeks
(9–30 weeks). The steroid-treated group was having
lower body mass index, less chronic kidney disease,
lower uric acid level, and lower score of tubular atrophy
and interstitial fibrosis than did the non-treated group
(Table 3).
Figure 1 shows the Kaplan–Meier curves of the rate of
renal recovery and risks of ESRD and mortality depend-
ing on the use of steroids. None of the renal outcomes,
including renal recovery and the risks of ESRD and
all-cause mortality, were different between the
steroid-treated and non-treated groups. Despite adjust-
ment of multiple variables, the steroid-treated group did
not have favorable outcomes compared with the
non-treated group (Table 4). To balance all of the ob-
served baseline variables between groups, we further
used 1:1 propensity score matching. Propensity scores
were estimated by logistic regression, with several vari-
ables, including age, sex, body mass index, diabetes mel-
litus, hypertension, chronic kidney disease, serum
creatinine levels at biopsy, uric acid levels, albumin
levels, proteinuria, hematuria, tubular atrophy and inter-
stitial fibrosis, leukocyte infiltration, dialysis at biopsy,
and serum creatinine levels at the time of kidney biopsy.
The steroid-treated group had similar rates of renal re-
covery at 6 months (58.5% vs. 50.0%; OR, 1.05; 95% CIs
0.258–4.269; P = 0.947), renal recovery at the last
follow-up (78.0% vs. 65.0%; HR 0.82; 95% CIs 0.401–
1.674; P = 0.583), ESRD (23.2% vs. 25.0%; HR 0.76; 95%
CIs 0.188–3.032; P = 0.693), and all-cause mortality
(14.6% vs. 20.0%; HR 0.33; 95% CIs 0.049–2.174; P =
0.248) compared with the non-treated group (Table 4).
In the regression models, diabetes mellitus, but not the
other variables, was associated with the renal recovery
rate (Additional file 1: Table S1).
Subgroup analysis was performed in the
steroid-treated group to determine whether factors re-
lated to steroid use, such as pulse therapy of
Table 2 Renal outcome classified by the etiology
Outcome All patients (n = 113) Idiopathic (n = 77) Drug induced (n = 25) Autoimmune (n = 5) Others (n = 6) P-valuea
Renal recovery at 6 months (%) 54.9 53.2 68.0 40.0 33.3 0.333
Renal recovery at last follow-up (%) 73.5 71.4 88.0 80.0 33.3 0.043
End-stage renal disease (%) 25.7 24.7 20.0 20.0 66.7 0.088
All-cause mortality (%) 17.7 15.6 16.0 0.0 66.7 0.029
aP-value was measured using the chi-square test between all groups
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methylprednisolone, initial steroid dose, and delay of
starting steroids affected renal outcomes. After ad-
justment of multiple variables, none of variables
were associated with renal recovery at 6 months,
including methylprednisolone pulse therapy (OR 1.02
vs. none; 95% CIs 0.987–2.210; P = 0.276), initial
steroid dose (OR 0.97 per 1 mg of prednisolone dose;
95% CIs 0.894–1.044, P = 0.381), and a delayed start
of steroids (OR 1.00 per 1 day of delay; 95% CIs
0.964–1.041; P = 0.924).
Pooled analysis
We performed pooled analysis on the effects of steroids
on the outcome of ESRD in drug-induced ATIN from
three studies [12, 14, 15], as well as the present study (n
= 347). We used the DerSimonian and Laird random ef-
fects model because of heterogeneity between studies.
There was no significant difference in progression of
ESRD between the steroid-treated and non-treated
groups (relative risk, 1.81; 95% CIs 0.599–5.474; P =
0.292) (Fig. 2).
Table 3 Baseline characteristics of idiopathic or drug-induced acute tubulointerstitial nephritis
Variable All subjects (n = 102) Steroid-treated group (n = 82) Non-treated group (n = 20) P-valuea
Age (year) 58.6 ± 14.9 58.1 ± 15.4 60.6 ± 13.0 0.501
Female (%) 41.2 39.0 50.0 0.371
Body mass index (kg/m2) 23.4 ± 3.5 22.9 ± 3.4 25.4 ± 3.3 0.005
Comorbidities (%)
Diabetes mellitus 31.4 29.3 40.0 0.354
Hypertension 42.2 37.8 60.0 0.072
Chronic kidney disease 11.8 7.3 30.0 0.012
Blood findings
Peak sCr (mg/dL) 4.57 (3.04–7.23) 4.67 (3.00–7.46) 4.43 (4.06–6.05) 0.879
sCr at biopsy (mg/dL) 3.73 (2.70–5.80) 3.89 (2.51–6.10) 3.40 (3.09–4.05) 0.458
Hemoglobin (g/dL) 10.0 ± 1.6 10.5 ± 1.7 9.9 ± 1.6 0.201
Cholesterol (mg/dL) 140.0 (121.0–167.0) 140.0 (121.0–166.0) 144.0 (122.0–186.0) 0.820
Uric acid (mg/dL) 6.1 (4.6–8.0) 5.9 (4.1–7.5) 7.5 (6.2–9.9) 0.005
Albumin (g/dL) 3.5 (3.1–3.9) 3.5 (3.1–3.9) 3.2 (2.9–4.0) 0.280
Proteinuria (%) 0.116
- or trace 28.4 24.4 45.0
1+ 33.3 36.6 20.0
2+ 25.5 28.0 15.0
≥ 3+ 12.7 11.0 20.0
Hematuria (%) 41.2 37.8 55.0 0.161
Pyuria (%) 57.8 56.1 65.0 0.470
uPCR (g/g) 1.2 (0.7–2.5) 1.3 (0.7–2.4) 0.9 (0.7–4.2) 0.676
Dialysis at biopsy (%) 29.4 30.5 25.0 0.629
TA/IF (%) 0.024
None 13.7 12.2 20.0
Milde 34.3 37.8 20.0
Moderate 40.2 42.7 30.0
Severe 11.8 7.3 30.0
Leukocyte infiltration (%) 0.514
Mild 17.6 15.9 25.0
Moderate 38.2 37.8 40.0
Severe 44.1 46.3 35.0
Follow-up duration (months) 34 (19–55) 34 (18–54) 27 (21–69) 0.508
aP-value was obtained from the Student’s t-test or the Mann-Whitney test
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Cytokine and chemokine analysis
The above results showed that steroid therapy did not
affect the overall outcomes of ATIN. Accordingly, we
need to adopt other treatment options to improve pa-
tient’s outcomes. Nevertheless, understanding of the
pathophysiology of ATIN is not clear. Therefore, we
attempted to determine which inflammatory cytokines
or chemokines are expressed in patients with ATIN.
Plasma levels of IL-1β, IFN-α2, tumor necrosis
factor-α, monocyte chemo-attractant protein-1, IL-6,
IL-8, IL-17A, IL-18, and IL-23 were higher in patients
with ATIN than in healthy individuals (Fig. 3a). Urine
levels of IFN-α2, monocyte chemo-attractant protein-1,
IL-6, IL-8, IL-12p70, and IL-17A were higher in pa-
tients with ATIN than in healthy individuals (Fig. 3b).
The other cytokines including IL-10, IFN-γ, IL-23,
IL-33 were not different between patients and healthy
individuals.
Discussion
ATIN is an important cause of tubular injury, but its
pathophysiology and treatment are not well understood.
The present study evaluated the effect of steroids in pa-
tients with idiopathic and drug-induced ATIN. However,
our results did not support an effect of steroids on renal
outcomes and patients’ survival. For the first time, we
performed cytokine and chemokine analyses in plasma
and urine before steroid treatment. We found that cer-
tain cytokines and chemokines were elevated in patients
with ATIN.
The present study showed that renal outcomes of
ATIN were significantly different depending on the eti-
ology. Drug-induced ATIN showed the most favorable
outcome (88.0% of renal recovery during the study
period), and malignancy-associated ATIN was the worst
(20%). The etiology should be considered to evaluate the
effects of steroid. Therefore, drug-induced and idio-
pathic ATIN were included in analysis of the effect of
steroids in our study. In these groups, steroid use did
not appear to play a significant role in renal recovery.
This trend remained consistent, even after matching was
performed. Subgroup analysis of the steroid-treated
group also showed that there was no significant differ-
ence in renal recovery according to pattern of steroid
use, such as methylprednisolone pulse therapy, steroid
dose, and a delayed start of steroids.
In drug-induced ATIN, steroids are recommended
after culprit drug withdrawal [8]. Although inconsist-
ent results have been shown in previous papers on
the steroid effect of ATIN [4], steroids are generally
used for treating ATIN. Previous retrospective studies
related to the effect of steroids on ATIN that com-
pared a steroid group and a non-steroid group are
shown in Table 5 [11–16]. Most patients with ATIN
in these studies were treated with steroids (59–87%),
and different criteria were applied to evaluate renal
recovery in each article. Three of these studies [12,
13, 16] showed that steroids were effective in renal
outcome, while the other three [11, 14, 15] did not.
Among the studies that analyzed the effect of steroids
on drug-induced ATIN, only one study [12] showed a
Fig. 1 Meta-analysis of end-stage renal disease in the steroid-treated
group compared with the non-treated group
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positive result of steroid use. These previous studies
and the current study do not provide clear evidence
to support steroid use.
The pathophysiology of ATIN is likely to be associ-
ated with hypersensitivity and immune reactions [9,
10], and steroid use is believed to have favorable ef-
fects on such mechanisms [24]. However, the detailed
mechanisms of ATIN are not clearly understood, and
thus, a treatment option for ATIN is currently lim-
ited. In addition to steroids, there could be other
treatment options such as immunosuppressive agents,
which are used to reduce the duration of steroid use
or to treat steroid-refractory cases. Mycophenolate
mofetil was introduced after steroids in patients with
ATIN [25]. Additionally, other agents, including
azathioprine and cyclosporine, were also prescribed in
some patients [17]. Recently, rituximab was adminis-
tered in immunoglobulin G4–related ATIN and re-
ported to be effective in a case report [26]. However,
these agents have not been proven as superior to ste-
roids and are not easily applicable to current clinical
practice.
Because patients with ATIN occasionally showed per-
ipheral eosinophilia and tissue eosinophilic infiltration as
well as extra-renal manifestations (e.g., skin rash), the
pathophysiology of ATIN had been considered to be
related with hypersensitivity reaction or Th2 cytokines
[9, 10]. The present study showed that inflammatory
cytokines and chemokines were elevated in patients
with ATIN compared with healthy individuals. Most
of patients with ATIN have a Th1 response with ele-
vated levels of TNF-α, monocyte chemo-attractant
protein-1, IL-6, and IL-8 in both urine and plasma.
The pattern of cytokine levels elevated in ATIN was
similar to that in renal ischemia-reperfusion model,
although some cytokines (e.g., INF-γ) were not evi-
dent in patient samples. Furthermore, levels of IL-10
and IL-33, as representative Th2 cytokines, were not
elevated in our patients. The findings suggest that
pathogenesis of ATIN may be different from that of
typical asthma or allergic rhinitis, which are known
as Th2- or hypersensitivity-related disease. Intri-
guingly, IL-12p70 levels, related to NK cells activity
[27], were elevated in urine, but not plasma, of
patients.
The underlying mechanisms could not be determined
by the present observations alone, but the cytokine assay
may provide a clue for investigating another potential
Fig. 2 Kaplan Meier curves of renal recovery (a), end-stage renal disease (b), and patients’ survival (c) between the steroid-treated and non-
treated groups. Differences were measured using the log rank test
Table 4 Renal outcome of unclear or drug-induced acute tubulointerstitial nephritis classified by steroid use












Renal recovery at 6 months
(%)
56.9 50.0 58.5 0.947 50.0 1.000
Renal recovery at last follow-
up (%)
75.5 65.0 78.0 0.583 75.0 0.490
End-stage renal disease (%) 23.5 25.0 23.2 0.693 35.0 0.490
All-cause mortality (%) 15.7 20.0 14.6 0.248 10.0 0.661
aAdjusted for age, sex, body mass index, diabetes mellitus, hypertension, chronic kidney disease, serum creatinine at kidney biopsy, uric acid, albumin, proteinuria,
hematuria, tubular atrophy and interstitial fibrosis, leukocytes infiltration, and dialysis at biopsy
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treatment agent. Many cytokine-targeting agents are
currently used in clinical practice such as TNF-α inhibi-
tor [28], and novel agents are in course of preparation to
various diseases such as IL-17Rα inhibitor [29]. This
cytokine analysis may be helpful in future application of
treatment on ATIN.
Although our data are informative, there are some lim-
itations. The present study was an observational study
and not a randomized, controlled trial on steroid use.
Accordingly, trials under control of baseline are required
for a definite conclusion. The definition of renal recov-
ery in the study focused on azotemia, and improvement
in proteinuria could not be evaluated due to lack of
follow-up data on urinalysis. Additionally, there were
many unknown etiologies in this study, and this pre-
cluded from performing subgroup analysis by etiology.
Cytokine levels after kidney biopsies were not examined,
which may provide more insights on pathophysiologic
significance.
Conclusion
Steroid use has minimal effect on the long-term course
of ATIN. Cytokine and chemokine results may help to
identify the pathophysiology of ATIN and to develop
Fig. 3 Cytokine and chemokine analysis in plasma (a) and urine (b) at the time of kidney biopsy in patients compared with samples of
healthy individuals
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new targeted therapies for ATIN in a future study. A fur-
ther study on the mechanism and its translation are re-
quired to develop novel agents against ATIN and to
finally improve patients’ outcomes.
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